The difference of patients in the validation cohort, grouped by 30-day ischaemic events
| Characteristics | Ischaemic events n=45 | No ischaemic events n=327 | P value |
| Age, years, m (IQR) | 57 (47–62) | 55 (49–62) | 0.443 |
| Male gender, n (%) | 19 (42.2%) | 158 (48.3%) | 0.868 |
| Comorbidities, n (%) | |||
| Hypertension | 18 (40.0%) | 124 (37.9%) | 0.788 |
| Dyslipidaemia | 6 (13.3%) | 29 (8.9%) | 0.337 |
| Diabetes mellitus | 14 (31.1%) | 91 (27.8%) | 0.647 |
| CA diseases | 6 (13.3%) | 25 (7.6%) | 0.196 |
| Ischaemic stroke or TIA | 30 (66.7%) | 165 (50.5%) | 0.042* |
| Ever-or-now smokers, n (%) | 18 (40.0%) | 115 (35.2%) | 0.527 |
| Regular drinkers, n (%) | 2 (4.4%) | 32 (9.8%) | 0.244 |
| Laboratory findings | |||
| Platelet count, ×109, m (IQR) | 216 (210–244) | 216 (206–229) | 0.215 |
| APTT, m (IQR) | 24.8 (23.2–30.4) | 24.8 (24.5–30.4) | 0.506 |
| PT, m (IQR) | 1 (1–1) | 1 (1–1) | 0.058 |
| Fibrinogen, g/L, m (IQR) | 2.80 (2.42–3.58) | 2.80 (2.34–3.33) | 0.498 |
| Aneurysm locations, n (%) | 0.198 | ||
| AcomA/ACA | 5 (11.1%) | 27 (8.3%) | |
| ICA | 30 (66.7%) | 201 (61.5%) | |
| MCA | 10 (22.2%) | 87 (26.6%) | |
| PC | 0 (0.0%) | 12 (3.7%) | |
| Aneurysm size, mL, m (IQR) | 6.4 (6.1–8.8) | 6.3 (6.0–8.7) | 0.499 |
| ASR (TEG-AA<50%), n (%) | 22 (48.9%) | 108 (33.0%) | 0.037* |
| ASR-CN score, m (IQR) | 4 (2–5) | 3 (2–4) | 0.036* |
| CYP2C19 metaboliser, n (%) | <0.001* | ||
| EM | 4 (8.9%) | 134 (41.0%) | |
| IM | 30 (66.7%) | 162 (49.5%) | |
| PM | 11 (24.4%) | 31 (9.5%) |
*The difference was significant.
ACA, anterior cerebral artery; AcomA, anterior communicating artery; APTT, activated partial thromboplastin time; ASR, aspirin resistance; ASR-CN, aspirin resistance in the Chinese population; CA, coronary artery; EM, extensive metaboliser; ICA, internal carotid artery; IM, intermediate metaboliser; MCA, middle cerebral artery; PC, posterior circulation; PM, poor metaboliser; PT, Prothrombin time; TEG-AA, arachidonic acid channel in the thromboelastography; TIA, transient ischaemic attack.